| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (NCT05174169) | NRG Oncology | 2022-07-08 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (NCT04164069) | Anne Noonan | 2020-09-02 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer (NCT04044430) | University of California, San Francisco | 2020-08-31 |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (NCT03803553) | Massachusetts General Hospital | 2020-04-16 |
| Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer (NCT04416490) | Boryung Pharmaceutical Co., Ltd | 2020-03-25 |
| Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery (NCT03958435) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2018-11-09 |
| Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (NCT03827044) | Royal Marsden NHS Foundation Trust | 2018-08-31 |
| LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy (NCT03255434) | Institut du Cancer de Montpellier - Val d'Aurelle | 2017-11-01 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment (NCT03422601) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2017-07-13 |
| Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection (NCT02836977) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2016-03-01 |
| Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer (NCT02129218) | Case Comprehensive Cancer Center | 2015-02-16 |
| Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy (NCT02280278) | Sun Yat-sen University | 2014-10-01 |
| Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer (NCT01890213) | Duke University | 2013-11-01 |
| Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer (NCT01606124) | Mayo Clinic | 2012-06-01 |
| Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer (NCT01191684) | City of Hope Medical Center | 2011-10-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (NCT01126346) | Wake Forest University Health Sciences | 2010-05-01 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer (NCT00551421) | National Cancer Institute (NCI) | 2007-10-01 |
| Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery (NCT00433576) | National Cancer Institute (NCI) | 2006-12-01 |
| Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors (NCT00138177) | National Cancer Institute (NCI) | 2005-07-01 |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer (NCT00134069) | National Cancer Institute (NCI) | 2005-06-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer (NCT00070122) | National Cancer Institute (NCI) | 2004-04-01 |
| Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (NCT00079274) | National Cancer Institute (NCI) | 2004-02-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated (NCT00025337) | National Cancer Institute (NCI) | 2001-09-01 |
| SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer (NCT00005818) | National Cancer Institute (NCI) | 2000-03-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Combination Chemotherapy in Treating Patients With Stage III Colon Cancer (NCT00003835) | National Cancer Institute (NCI) | 1999-05-01 |
| Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer (NCT00019006) | National Cancer Institute (NCI) | 1995-03-01 |